The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease
Open accessAbstract
On June 30, 2009, the United States Food and Drug Administration (FDA) approved ferumoxytol (Feraheme™ injection, AMAG Pharmaceuticals), an iron‐containing product for intravenous (IV) administration, for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD). The safety and efficacy of ferumoxytol were assessed in three randomized, open‐label, controlled clinical trials. Two trials evaluated patients with nondialysis dependent CKD and a third trial assessed patients undergoing hemodialysis. Randomization was either to ferumoxytol or oral iron. Ferumoxytol was administered as two 510 mg IV injections, separated by 3–8 days. Oral iron, Ferro‐Sequels®, was administered at a dose of 100 mg twice daily for 21 days. In all three clinical trials, ferumoxytol administration increased the mean blood hemoglobin (Hgb) concentrations by ∼1.0 g/dL over the 35 day period, a mean increase that was greater than what was observed in patients receiving oral iron. Patients receiving ferumoxytol also had increases in blood transferrin saturation (TSAT) and ferritin values. For the proposed ferumoxytol dosing regimen, 4.9% of patients had serum ferritin ≥800 ng/mL and TSAT ≥50% post‐treatment. The most important ferumoxytol safety concerns were hypersensitivity reactions and/or hypotension. Anaphylaxis or anaphylactoid reactions were reported in 0.2% of subjects, and other adverse reactions potentially associated with hypersensitivity (e.g., pruritus, rash, urticaria, or wheezing) were reported in 3.7%. Hypotension was observed in 1.9%, including three patients with serious hypotensive reactions. Ferumoxytol administration may transiently affect the diagnostic ability of magnetic resonance imaging and the drug label provides further information regarding this effect. Am. J. Hematol. 2010. Published 2010 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Eckardt, K.-U., Tsukamoto, Y., Levin, A., Coresh, J., Rossert, J., Zeeuw, D. D. E., Hostetter, T. H., Lameire, N., & Eknoyan, G. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00365.x · Cited by 3,946
Assessing Iron Status: Beyond Serum Ferritin and Transferrin Saturation
Wish, J. B. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01490506 · Cited by 556
KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 Update
National Kidney Foundation (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.11.017 · Cited by 347
Shepshelovich, D., Rozen-Zvi, B., Avni, T., Gafter, U., & Gafter-Gvili, A. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.04.018 · Cited by 322
Iron and infection: the heart of the matter
Bullen, J. J., Rogers, H. J., Spalding, P. B., & Ward, C. G. (2005) · FEMS Immunology & Medical Microbiology · doi:10.1016/j.femsim.2004.11.010 · Cited by 273
Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease
Agarwal, R., Vasavada, N., Sachs, N. G., & Chase, S. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00648.x · Cited by 261
Strategies for iron supplementation: Oral versus intravenous
Macdougall, I. C. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.055suppl.69061.x · Cited by 199
Ferumoxytol as an Intravenous Iron Replacement Therapy in Hemodialysis Patients
Provenzano, R., Schiller, B., Rao, M., Coyne, D., Brenner, L., & Pereira, B. J. G. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02840608 · Cited by 187
Silverberg, D. S., Iaina, A., Peer, G., Kaplan, E., Levi, B. A., Frank, N., Steinbruch, S., & Blum, M. (1996) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(96)90546-6 · Cited by 173
Iron Status and Hemoglobin Level in Chronic Renal Insufficiency
Hsu, C.-Y., McCulloch, C. E., & Curhan, G. C. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000034200.82278.dc · Cited by 172
Rozen-Zvi, B., Gafter-Gvili, A., Paul, M., Leibovici, L., Shpilberg, O., & Gafter, U. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.05.033 · Cited by 163
Iron overload following red blood cell transfusion and its impact on disease severity
Ozment, C. P., & Turi, J. L. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2008.09.010 · Cited by 159
Safety of Ferumoxytol in Patients With Anemia and CKD
Singh, A. K., Patel, T. V., Hertel, J., Bernardo, M. V., Kausz, A., & Brenner, L. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.08.001 · Cited by 147
Physicochemical properties of ferumoxytol, a new intravenous iron preparation
Balakrishnan, V. S., Rao, M., Kausz, A. T., Brenner, L., Pereira, B. J. G., Frigo, T. B., & Lewis, J. M. (2009) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2009.02130.x · Cited by 144
Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin
Wingard, R. L., Parker, R. A., Ismail, N., & Hakim, R. M. (1995) · American Journal of Kidney Diseases · doi:10.1016/0272-6386(95)90105-1 · Cited by 139
Espósito, B. P., Breuer, W., Slotki, I. N., & Cabantchik, Z. I. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2002.0320s1042.x · Cited by 116
Iron deficiency in patients with renal failure
Nissenson, A. R., & Strobos, J. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.055suppl.69018.x · Cited by 85
Safety Issues With Intravenous Iron Products in the Management of Anemia in Chronic Kidney Disease
Hayat, A. (2008) · Clinical Medicine & Research · doi:10.3121/cmr.2008.811 · Cited by 62
Kalantar‐Zadeh, K., Streja, E., Miller, J. E., & Nissenson, A. R. (2009) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2008.12.008 · Cited by 60
Intravenous iron for the treatment of predialysis anemia
Silverberg, D. S., Blum, M., Agbaria, Z., Schwartz, D., Zubkov, A., Yachnin, T., & Iaina, A. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.055suppl.69079.x · Cited by 54
Iron therapy for renal anemia: how much needed, how much harmful?
Hörl, W. H. (2007) · Pediatric Nephrology · doi:10.1007/s00467-006-0405-y · Cited by 48
Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease
Agarwal, R., Rizkala, A. R., Kaskas, M. O., Minasian, R., & Trout, J. R. (2007) · Kidney International · doi:10.1038/sj.ki.5002422 · Cited by 43
Jacobs, P., Johnson, G., & Wood, L. (1984) · PubMed · Cited by 35
Considerations for optimal iron use for anemia due to chronic kidney disease
Hudson, J. Q., & Comstock, T. J. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80135-1 · Cited by 35
Indices of iron status in continuous ambulatory peritoneal dialysis patients
Domrongkitchaiporn, S., Jirakranont, B., Atamasrikul, K., Ungkanont, A., & Bunyaratvej, A. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70104-6 · Cited by 35
Issues Related to Iron Replacement in Chronic Kidney Disease
Agarwal, R., & Warnock, D. G. (2002) · Seminars in Nephrology · doi:10.1053/snep.2002.35972 · Cited by 34
Ferumoxytol as a New, Safer, Easier-to-Administer Intravenous Iron: Yes or No?
Auerbach, M. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.09.006 · Cited by 25
Cited by
Ulbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00589 · Cited by 1,730
Zanganeh, S., Hutter, G., Spitler, R., Lenkov, O., Mahmoudi, M., Shaw, A., Pajarinen, J. S., Nejadnik, H., Goodman, S., Moseley, M., et al. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2016.168 · Cited by 1,647
Imaging and drug delivery using theranostic nanoparticles
Janib, S. M., Moses, A. S., & MacKay, J. A. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.08.004 · Cited by 1,248
Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine
Donahue, N. D., Acar, H., & Wilhelm, S. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.04.008 · Cited by 944
In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles
Arami, H., Khandhar, A., Liggitt, D., & Krishnan, K. M. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00541h · Cited by 830
Metadata
- Authors
- Lu, M., Cohen, M. H., Rieves, D., & Pazdur, R.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2010-04-21
- Volume
- 85
- Issue
- 5
- Pages
- 315-319
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W1974023961
- Cited by
- 443
- References
- 27
- FWCI
- 13.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.